No Data
No Data
BioNTech SE (NASDAQ:BNTX) Surges 4.6%; Private Equity Firms Who Own 43% Shares Profited Along With Institutions
CCORF Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $171.44
Express News | Form 144 | BioNTech(BNTX.US) 10% Stockholder Proposes to Sell 5.26 Million in Common Stocks
European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading
BioNTech Price Target Raised to $171.44/Share From $171.00 by Canaccord Genuity
BioNTech Is Maintained at Buy by Canaccord Genuity